C. Dupin (Paris, France), O. Torre (Milano (MI), Italy)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Lung fibrosis in Pulmonary Alveolar Proteinosis (PAP): different stages of a syndrome or distinct diseases? F. Mariani (Pavia (PV), Italy), C. Infusino (Pavia (PV), Italy), S. Lettieri (Pavia (PV), Italy), D. Piloni (Pavia (PV), Italy), M. Bosio (Pavia (PV), Italy), A. De Silvestri (Pavia (PV), Italy), A. Corino (Pavia (PV), Italy), I. Campo (Pavia (PV), Italy)
|   |
Familial Pulmonary Fibrosis: experience from a tertiary hospital J. Pinto (Porto, Portugal), P. Mota (Porto, Portugal), N. Melo (Porto, Portugal), A. Morais (Porto, Portugal), H. Novais E Bastos (Porto, Portugal)
|   |
Lymphangioleiomyomatosis – experience of a university hospital M. Baptista (Covilhã, Portugal), N. Melo (Porto, Portugal), P. Mota (Porto, Portugal), H. Novais E Bastos (Porto, Portugal), S. Guimarães (Porto, Portugal), C. Souto-Moura (Porto, Portugal), A. Carvalho (Porto, Portugal), J. Jesus (Porto, Portugal), R. Cunha (Porto, Portugal), A. Morais (Porto, Portugal)
|   |
LYMPHANGIOLEIOMYOMATOSIS AND SIROLIMUS: MEDIUM-TERM IMPACT ON PULMONARY FUNCTION M. Garcia Moyano (Barakaldo, Spain), A. Urrutia (Barakaldo, Spain), L. Serrano (Barakaldo, Spain), A. Gómez (Barakaldo, Spain), S. Castro (Barakaldo, Spain), I. González (Barakaldo, Spain), J. Solorzano (Barakaldo, Spain), C. Jaca (Barakaldo, Spain), P. Ansola (Barakaldo, Spain), M. Iriberri (Barakaldo, Spain)
|   |
Retrospective evaluation of our cohort of CTD-ILD RA patients treated with Rituximab: 5 years follow up. F. Bini (Garbagnate Milanese, Italy), A. De Lauretis (Garbagnate Milanese, Italy), C. Arosio (Garbagnate Milanese, Italy), B. Bodini (Garbagnate Milanese, Italy), S. Zucchetti (Garbagnate Milanese, Italy), M. Papetti (Garbagnate Milanese, Italy), A. Vaghi (Garbagnate Milanese, Italy)
|   |
Nitrofurantoin Induced Pulmonary Fibrosis: A Case Series S. Naureen (Hull, United Kingdom), S. Faruqi (Hull, United Kingdom), S. Hart (Hull, United Kingdom), N. Jawad (Hull, United Kingdom), N. Kennan (Hull, United Kingdom)
|   |
Experience with antifibrotics treatment in progressive interstitial lung diseases non-IPF A. Llanos-González (SANTA CRUZ DE TENERIFE, Spain), S. García Gil (SANTA CRUZ DE TENERIFE, Spain), J. Bonilla Arjona (SANTA CRUZ DE TENERIFE, Spain), S. García Hernández (SANTA CRUZ DE TENERIFE, Spain), V. Hernández García (SANTA CRUZ DE TENERIFE, Spain), P. Pérez De Armas (SANTA CRUZ DE TENERIFE, Spain), N. Mesa León (SANTA CRUZ DE TENERIFE, Spain), O. Acosta Fernández (SANTA CRUZ DE TENERIFE, Spain)
|   |
Lung functional decline in patients with Interstitial Pneumonia with Autoimmune Features (IPAF) A. Nagy (Mosonmagyaróvár, Hungary), E. Palmer (Budapest, Hungary), E. Bárczi (Budapest, Hungary), A. Farkas (Budapest, Hungary), T. Erdélyi (Budapest, Hungary), K. Vincze (Budapest, Hungary), N. Eszes (Budapest, Hungary), A. Bohács (Budapest, Hungary), V. Müller (Budapest, Hungary)
|   |
Role of the inflammasome in the pathophysiology of antisynthetase-associated interstitial lung disease. A. Vega-Sanchez (Ciudad de Mexico, Mexico), E. Ramos-Martínez (Ciudad de Mexico, Mexico), I. Buendía-Roldan (Ciudad de Mexico, Mexico), G. Pérez-Rubio (Ciudad de Mexico, Mexico), R. Falfán-Valencia (Ciudad de Mexico, Mexico), M. Mejía (Ciudad de Mexico, Mexico), J. Rojas-Serrano (Ciudad de Mexico, Mexico)
|  |
Definition of progressive fibrosing interstitial lung diseases and approach to the patientPosition paper of Czech Respiratory Society M. Šterclová (Praha, Czech Republic), M. Doubkova (Brno, Czech Republic), R. Kralova (Pardubice, Czech Republic), P. Pohunek (Prague, Czech Republic), V. Bartos (Hradec Kralove, Czech Republic), V. Lostakova (Olomouc, Czech Republic), P. Musilova (Jihlava, Czech Republic), M. Vasakova (Prague, Czech Republic)
|   |
Retrospective evaluation of our cohort of patients with chronic estrinsic allergic alveolitis. F. Bini (Garbagnate Milanese, Italy), M. Papetti (Garbagnate Milanese, Italy), U. Zanini (Garbagnate Milanese, Italy), B. Bodini (Garbagnate Milanese, Italy), P. Faverio (Monza, Italy), A. Vaghi (Garbagnate Milanese, Italy), G. Pepe (Garbagnate Milanese, Italy), D. Colombo (Legnano, Italy)
|   |
Late Breaking Abstract - B cells are not involved in the regulation of adenoviral TGF-ß1- or bleomycin-induced lung fibrosis in mice M. Moog (Hannover, Germany), C. Hinze (Hannover, Germany), L. Knudsen (Hannover, Germany), D. Deluca (Hannover, Germany), T. Welte (Hannover, Germany), M. Kolb (Hamilton, Canada), U. Maus (Hannover, Germany)
|   |
Late Breaking Abstract - Development of a self-management package for pulmonary fibrosis: an international Delphi study J. Lee (Melbourne, Australia), G. Tikellis (Melbourne, Australia), A. Holland (Melbourne, Australia)
|   |